Evaluation of the fatigue symptom in patients with cancer and associated clinical problems;Kanser hastalarinda halsizlik semptomunun deǧerlendirilmesi ve birlikte görülen klinik problemler

Gulhane Medical Journal

Volumn 50, Issue 2, 2008, Pages 141-146

  Yavuzşen, Tuǧba ^a   Kömürcü, Şeref ^b,c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b GATF Tibbi Onkoloji BD ^*

^c GATF Tibbi Onkoloji BD   (Turkey)

Author keywords

Cancer; Fatigue; Supportive care; Weakness

Indexed keywords

EID: 47649092758     PISSN: 13020471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Donnelly S, Walsh D. The symptoms of advanced cancer. Semin Oncol 1995; 22 (Suppl 3): 67-72.
2. Stone P, Hardy J, Broadley K, Tookman AJ, Kurowska A, A'Hern R. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 1999; 79: 1479-1486.
3. Stone P, Richards M, A'Hern R, Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000; 11: 651-567.
4. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528-538.
5. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000; 8: 175-179.
6. Lawrence DP, Kupelnick B, Miller K, et al. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004; 32: 40-50.
7. Curt GA, Breibart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 2000; 5: 353-360.
8. Mock V, Atkinson A, Barsevick A, et al. National Comprehensive Cancer Network. NCCN practice guidelines for cancer-related fatigue. Version 1 2004.
9. Jacobsen PB. Assessment of fatigue in cancer patients. J Natl Cancer Ins Monogr 2004; 32: 93-97.
10. Donnelly S, Walsh D, Rybicki L. The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 1995; 11: 27-32.
11. Oi-Ling K, Man-Wah DT, Kam-Hing DN. Symptom distress as rated by advanced cancer patients, caregivers and physicians in the last week of life. Palliat Med 2005; 19: 228-233.
12. Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in United States sample of cancer survivors. J Clin Oncol 2001; 19: 3385-3391.
13. Okuyama T, Akechi T, Kugaya A, et al. Factors correlated with fatigue in disease-free breast cancer patients: application of the Cancer Fatigue Scale. Support Care Cancer 2000; 8: 215-222.
14. Hjermstad MJ, Fossa SD, Oldervoll L, Holte H, Jacobsen AB, Loge JH. Fatigue in long-term Hodgkin's Disease survivors: a follow-up study. J Clin Oncol 2005; 23: 6587-6595.
15. Vogelzang NJ, Breitbart W, Cella D, et al. The Fatigue Coalition. Patient, caregiver, and oncologist perceptions cancer-related fatigue: results of a tripart assessment survey. Semin Oncol 1997; 34: 4-12.
16. Cella D, Paul D, Yount S, et al. What are the most important symptoms targets when treating advanced cancer? Survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21: 526-535.
17. Maltoni M, Nanni O, Scarpi E, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. J Pain Symptom Manage 1999; 17: 240-247.
18. Llobera J, Esteva M, Rifa J, et al. Terminal cancer: duration and prediction of survival time. Eur J Cancer 2000; 36: 2036-2043.
19. Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recomendations-a study by the Steering Commitee of the European Association for Palliative Care. J Clin Oncol 2005; 23: 6240-6248.
20. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003; 97: 2919-2925.
21. Turner R, Anglin P, Burkes R, et al. Epoetin alfa in cancer patients: evidence based guidelines. J Pain Symptom Manage 2001; 22: 954-965.
22. Harper P, Littlewood T. Anemia of cancer: impact on patient fatigue and long-term outcome. Oncology 2005; 69 (Suppl 2): 2-7.
23. Stasi R, Abriani L, Beccaglia P, et al. Cancer-related fatigue. Cancer 2003; 98: 1786-1801.
24. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-5972.
25. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2005; 362: 1255-1260.
26. Monti M, Castellani L, Berlusconi A, et al. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage 1997; 13: 18-22.
27. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003; 4: 686-694.
28. Kurzrock R. The role of cytokines in cancer related fatigue. Cancer 2001; 92: 1684-1688.
29. Gutstein HB. The biologic basis of fatigue. Cancer 2001; 92: 1678-1683.
30. Schwartz AL, Thompson JA, Masood N. Interferon induced fatigue in patienst with melanoma: a pilot study of exercise and methylphenidate. Oncol Nursing Forum 2002; 29: E85-E90.
31. Farag SS, George SL, Lee EJ, et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly paients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res 2002; 8: 2812-2819.
32. Naglieri E, Lopez M, Lellli G, et al. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma. Anticancer Res 2002; 22: 3045-3051.
33. Demitrac MA. Neuroendocrine aspects of chronic fatigue syndrome: a commentary. Am J Med 1998; 105: 11S-14S.
34. Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998; 2: 74-78.
35. Neri B, Garosi VL, Intini C. Effect of medroxyprogesterone acetate on the quality of life of the oncology patient: a multicentric cooperative study. Anticancer Drugs 1997; 8: 459-465.
36. Westman G, Bergman B, Albertsson M, et al. Megestrol acetate in advanced, progressive, hormone insensitive cancer. Effects on the quality of life: a placebo-controlled, randomized, multicentre trial. Eur J Cancer 1999; 35: 586-595.
37. Klinkenberg M, Willems DL, van der Wal G, et al. Symptom burden in the last week of life. J Pain Symptom Manage 2004; 27: 5-13.
38. Tamburini M, Brunelli C, Rosso S, et al. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 1996; 11: 32-41.
39. Lawlor PG, Gagnon B, Mancini IL, et al. Delirium a predictor of survival in older patients with advanced cancer. Arch Intern Med 2000; 160: 2866-2868.
40. Winnigham ML. Strategies for managing cancer-related fatigue syndrome. Cancer 2001; 92: 988-997.
41. Dimeo F, Schmittel A, Fietz T, et al. Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. Ann Oncol 2004; 15: 1237-1242.
42. Jacobsen PB, Weitzner MA. Evaluating the relationship of fatigue to depression and anxiety in cancer patients. In: Portenoy R, Bruera E (eds). Issues in Palliative Care Research. New York: Oxford University Press, 2003: 127-150.
43. Winell J, Roth AJ. Depression in cancer patients. Oncology 2004; 18: 1554-1560.
44. Spiegel D, Giese-Davis J. Depression and cancer: mechanism and disease progression. Biol Psychiatry 2003; 54: 269-282.
45. Derogatis LR, Abeloff MD, Melisaratos N. Psychological coping mechanism and survival time in metastatic breast cancer. JAMA 1979; 242: 1504-1508.
46. Loberiza FR, Rizzo JD, Bredeson CN, et al. Association of depressive syndrome and early deaths among patients after stem cell transplantation for malignant diseases. J Clin Oncol 2002; 20: 2118-2126.
47. Stommel M, Given BA, Given CW. Depression and functional status as predictors of death among cancer patients. Cancer 2002; 94: 2719-2727.
48. Schwartz AL. Daily fatigue patterns and effect of exercise in women with breast cancer. Cancer Pract 2000; 160: 526-534.
49. Hanna A, Sledge G, Mayer ML, et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2005 Aug 12; [Epub ahead of print].
50. Homsi J, Walsh D, Nelson KA. Psychostimulants in supportive care. Support Care Cancer 2000; 8: 385-397.
51. Homsi J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 2001; 18: 403-407.
52. Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001; 18: 187-192.
53. Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003; 21: 4439-4443.
54. Marrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from The University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003; 21: 4635-4641.
55. Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 2003; 21: 1937-1943.
56. Mercado G, Adelstein DJ, Saxton JP, et al. Hypothyroidism. A frequent event after radiotherapy and after chemotherapy for patients with head and neck carcinoma. Cancer 2001; 92: 2892-2897.
57. Kumar N, Allen KA, Riccardi D, et al. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidsm the culprit? Breast Cancer Res Treat 2004; 83: 149-159.
58. Fleishman SB. Treatment of symptom clusters: pain, depression, and fatigue. J Natl Cancer Inst Monogr 2004; 32: 119-123.
59. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisone in terminal cancer patients: a prospective randomized double blind study. Cancer Treat Reports 1985; 69: 751-754.
60. Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. Br Med J 1984; 288: 27.
61. Moertel CG, Schutt AJ, Reitemeier RJ, et al. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33: 1607-1609.
62. Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. Br Med J 2003; 327: 195-198.
63. Vigano A, Dorgan M, Buckingham J, et al. Survival prediction in terminal cancer patients: a systematic review of medical literature. Palliat Med 2000; 14: 363-374.
64. Courneya KS, Mackey JR, Bell GJ, et al. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol 2003; 21: 1660-1668.
65. Mock V, Frangakis C, Davidson NE, et al. Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncology 2005; 14: 464-477.
66. Mock V, Pickett M, Ropka ME, et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract 2001; 9: 119-127.
67. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 2001; 28: 465-470.
68. Mercandate S, Girelli D, Casuccio A. Sleep disorders in advanced cancer patients: prevalence and factors associated. Support Care Cancer 2004; 12: 355-359.
69. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000; 18: 743-753.
70. Beach P, Siebeneck B, Buderer NF, Ferner T. The relationship between fatigue and nutritional status in patients receiving radiation therapy to treat lung cancer. Oncol Nurs Forum 2001; 28: 1027-1031.